MannKind Announces Clearance from PMDA to Initiate Phase 3 Clinical Trial (ICoN-1) in Japan Evaluating Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease
18 sept. 2024 06h15 HE
|
MannKind
MannKind Announces Clearance from PMDA to Initiate Phase 3 Clinical
Trial (ICoN-1) in Japan Evaluating Clofazimine Inhalation Suspension
for the Treatment
マンカインド (MannKind) 、非結核性抗酸菌症（NTM）肺疾患治療用クロファジミン (Clofazimine) 吸入懸濁液の日本における第 3 相臨床試験（ICoN-1）開始に向けたPMDA承認取得を発表
18 sept. 2024 06h15 HE
|
MannKind
韓国とオーストラリアの保健当局からも承認取得、台湾は2024年第4四半期に承認取得予定米国で初の患者無作為化 コネチカット州ダンバリ, Sept. 18, 2024 (GLOBE NEWSWIRE) -- 内分泌疾患および希少肺疾患患者を対象とした革新的な吸入治療薬および機器の開発・商業化に取り組んでいる マンカインド・コーポレーション (MannKind Corporation)...
MannKind to Present at 2024 Cantor Fitzgerald Global Healthcare Conference
10 sept. 2024 16h30 HE
|
MannKind
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Sept. 10, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative inhaled...
MannKind to Present at Upcoming Conferences
27 août 2024 16h30 HE
|
MannKind
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Aug. 27, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative inhaled...
Kent Kresa to Retire from MannKind’s Board of Directors; Steven B. Binder to be Appointed to the Board
14 août 2024 08h00 HE
|
MannKind
KENT KRESA TO RETIRE FROM MANNKIND’S BOARD OF DIRECTORS; STEVEN B. BINDER TO BE APPOINTED TO THE BOARD
MannKind Corporation Reports 2024 Second Quarter Financial Results: Provides Clinical Development Update
07 août 2024 08h00 HE
|
MannKind
2Q 2024 Total revenues of $72M; +49% vs. 2Q 2023YTD 2024 Total revenues of $139M; +55% vs. YTD 2023YTD 2024 Net income of $9 million; Non-GAAP net income of $29 millionAdvances two orphan lung...
MannKind Launches Educational Website to Raise Awareness of NTM Lung Disease
31 juil. 2024 06h30 HE
|
MannKind
MannKind Launches Educational Website to Raise Awareness of NTM Lung Disease
MannKind Corporation to Hold 2024 Second Quarter Financial Results Conference Call on August 7, 2024
30 juil. 2024 16h30 HE
|
MannKind
MANNKIND CORPORATION TO HOLD 2024 SECOND QUARTER FINANCIAL RESULTS CONFERENCE CALL ON AUGUST 7, 2024
INHALE-3 Study Reveals Positive Readout in Head-to-Head Comparison of Inhaled Insulin vs. Usual Care in T1D; New Data Presented at American Diabetes Association’s 84th Scientific Sessions
22 juin 2024 08h00 HE
|
MannKind
INHALE-3 STUDY REVEALS POSITIVE READOUT IN HEAD-TO-HEAD COMPARISON OF INHALED INSULIN VS. USUAL CARE IN T1D; NEW DATA PRESENTED
Inhale-3 Study Results to be Presented During a 90-Minute Symposium on Saturday, June 22 at the American Diabetes Association’s 84th Scientific Sessions
05 juin 2024 06h45 HE
|
MannKind
INHALE-3 STUDY RESULTS TO BE PRESENTED DURING A 90-MINUTE SYMPOSIUM ON SATURDAY, JUNE 22 AT THE AMERICAN DIABETES ASSOCIATION’S 84TH SCIENTIFIC SESSIONS